AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19318434 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele of the PARP1 rs1136410 variant
Number of subjects: 1000
Study 19318434 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the G allele of the PRKDC rs7003908 variant
Number of subjects: 1000
Study 19318434 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype modeling of ERCC2 rs13181, ERCC1 rs3212986, and GLTSCR1 rs1035938
Number of subjects: 1000
Study 17453555 — intervention group
Group type: EXPERIMENTAL
Intervention: Carers Assessment of Difficulties Index (CADI)
Number of subjects: 232
Study 15502027 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane 0.6% + air + O(2) 30%
Number of subjects: 12
Study 15502027 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol 120 microg . kg(‐1) . min(‐1) + air + O(2) 30%
Number of subjects: 12
Study 15502027 — intervention group
Group type: COMPARATOR
Intervention: isoflurane 0.4% + N(2)O 70% + O(2) 30%
Number of subjects: 12
Study 15502027 — intervention group
Group type: COMPARATOR
Intervention: isoflurane 0.6% + N(2)O 70% + O(2) 30%
Number of subjects: 12
Study 11201624 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation
Number of subjects: 81
Study 11201624 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation
Number of subjects: 81
Study 8959084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (20 mg) administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Number of subjects: 21
Study 8959084 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Number of subjects: 21
Study 1488563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (PImax)
Number of subjects: 20
Study 1488563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal expiratory pressure (PEmax)
Number of subjects: 20
Study 3893730 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (initial dose 750 mg, additional 250-500 mg as needed, max 5 tablets in 24h)
Number of subjects: 41
Study 3893730 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 41
Study 3893730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31610549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg/d or 15 mg/d, according to renal function)
Number of subjects: 190
Study 31610549 — intervention group
Group type: COMPARATOR
Intervention: Dose‐adjusted vitamin K antagonists (VKAs)
Number of subjects: 190
Study 31610549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 190
Study 29758152 — intervention group
Group type: EXPERIMENTAL
Intervention: OC15AB mouthwash
Number of subjects: 40
Study 29758152 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 40
Study 27321312 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + DPP4 inhibitors
Number of subjects: 0
Study 27321312 — intervention group
Group type: COMPARATOR
Intervention: Metformin + insulin-secretagogues (IS)
Number of subjects: 0
Study 24382299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parent-student intervention
Number of subjects: 2937
Study 24382299 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2937
Study 22128201 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) with standard breakfast
Number of subjects: 72
Study 22128201 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) in fasted state
Number of subjects: 72
Study 18083064 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetsuit (WS)
Number of subjects: 12
Study 18083064 — intervention group
Group type: COMPARATOR
Intervention: Swimsuit (SS)
Number of subjects: 12
Study 17484581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous request interpretation with prior verbal and physical contact with the ball
Number of subjects: 0
Study 17484581 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable cues to the ball's spatial location
Number of subjects: 0
Study 17484581 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict between spatial information and color cue
Number of subjects: 0
Study 17484581 — intervention group
Group type: COMPARATOR
Intervention: Control condition with mere presence of the experimenter
Number of subjects: 0
Study 16326875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel/Enduron articulation
Number of subjects: 114
Study 16326875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel/Hylamer cup
Number of subjects: 114
Study 16326875 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium oxide ceramic/Enduron
Number of subjects: 114
Study 16326875 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium oxide ceramic/Hylamer
Number of subjects: 114
Study 16326875 — intervention group
Group type: COMPARATOR
Intervention: Control group (stainless steel/Hylamer vs zirconium oxide ceramic/Hylamer)
Number of subjects: 114
Study 12494713 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) using glass-ionomer (GI) and compomer materials
Number of subjects: 401
Study 12494713 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention treatment (MIT) using glass-ionomer (GI) and compomer materials
Number of subjects: 401
Study 12494713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment during restoration procedures
Number of subjects: 401
Study 12494713 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of restorations after one year
Number of subjects: 401
Study 12494713 — intervention group
Group type: EXPERIMENTAL
Intervention: Success of restorations per region
Number of subjects: 401
Study 9535153 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 8
Study 9535153 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily)
Number of subjects: 8
Study 9535153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9535153 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and Losartan
Number of subjects: 8
Study 7710392 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.00-mm ablation diameter
Number of subjects: 80
Study 7710392 — intervention group
Group type: COMPARATOR
Intervention: 5.00-mm ablation diameter
Number of subjects: 80
Study 2533042 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg twice daily for 19 patients, 10 mg twice daily for 2 patients)
Number of subjects: 21
Study 2533042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2533042 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 21
Study 335882 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable-protein diet
Number of subjects: 3
Study 335882 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable-protein diet with lactulose
Number of subjects: 3
Study 335882 — intervention group
Group type: COMPARATOR
Intervention: Animal-protein diet
Number of subjects: 3
Study 31813636 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) delivered as 34 Gy of brachytherapy or 38.5 Gy of external beam radiation therapy in 10 fractions over 5 treatment days within an 8-day period.
Number of subjects: 4216
Study 31813636 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed.
Number of subjects: 4216
Study 31813636 — intervention group
Group type: EXPERIMENTAL
Intervention: APBI
Number of subjects: 4216
Study 31813636 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 4216
Study 29267556 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal computer tomography (CT)
Number of subjects: 66
Study 29267556 — intervention group
Group type: COMPARATOR
Intervention: Isolated serial clinical exam (SCE)
Number of subjects: 66
Study 26185423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) formulation of cilostazol 200 mg every 24 hours
Number of subjects: 30
Study 26185423 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation of cilostazol 100 mg every 12 hours
Number of subjects: 30
Study 23448818 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed administration of rabbit antithymocyte globulin
Number of subjects: 231
Study 23448818 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (control group)
Number of subjects: 231
Study 21063786 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute migraine treatment
Number of subjects: 330
Study 19623197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (20,000 IU for infants ≤1 year; 45,000 IU for infants >1 year)
Number of subjects: 584
Study 19623197 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily)
Number of subjects: 584
Study 19623197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin A-zinc supplement
Number of subjects: 584
Study 19623197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study 17236889 — intervention group
Group type: EXPERIMENTAL
Intervention: ER metoprolol 0.2 mg/kg
Number of subjects: 140
Study 17236889 — intervention group
Group type: EXPERIMENTAL
Intervention: ER metoprolol 1.0 mg/kg
Number of subjects: 140
Study 17236889 — intervention group
Group type: EXPERIMENTAL
Intervention: ER metoprolol 2.0 mg/kg
Number of subjects: 140
Study 17236889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15590583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prinomastat
Number of subjects: 158
Study 15590583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 11115719 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix‐B (10 microg hepatitis B surface antigen)
Number of subjects: 0
Study 11115719 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombivax (5 microg hepatitis B surface antigen)
Number of subjects: 0
Study 9306340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive treatment (felodipine, metoprolol, or ramipril)
Number of subjects: 39
Study 8374373 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and non-steroidal anti-inflammatory drugs
Number of subjects: 476
Study 8374373 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs prescribed for longer than five years
Number of subjects: 476
Study 8374373 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol or other drugs
Number of subjects: 476
Study 3737444 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 I.U. lysine‐vasopressin
Number of subjects: 34
Study 3737444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31135283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tube
Number of subjects: 0
Study 31135283 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed tubes
Number of subjects: 0
Study 31135283 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed laryngoscope blades
Number of subjects: 0
Study 29274179 — intervention group
Group type: EXPERIMENTAL
Intervention: Single motivational interview (MI)
Number of subjects: 462
Study 29274179 — intervention group
Group type: EXPERIMENTAL
Intervention: Single motivational interview plus cognitive‐behavioural self‐help workbook (MI + W)
Number of subjects: 462
Study 29274179 — intervention group
Group type: EXPERIMENTAL
Intervention: Single motivational interview plus workbook plus four booster follow‐up telephone interviews (MI + W + B)
Number of subjects: 462
Study 29274179 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 462
Study 27891769 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 24
Study 26195963 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine therapy with pelvic floor exercise (Group A)
Number of subjects: 58
Study 26195963 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercise only (Group B)
Number of subjects: 58
Study 24266969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 297
Study 24266969 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 297
Study 24266969 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TACex)
Number of subjects: 297
Study 21179038 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailing of self-sampler
Number of subjects: 619
Study 21179038 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampler at request
Number of subjects: 619
Study 21179038 — intervention group
Group type: COMPARATOR
Intervention: HPV test at clinic
Number of subjects: 619
Study 21179038 — intervention group
Group type: COMPARATOR
Intervention: Standard recall letters (Pap-test)
Number of subjects: 619
Study 18307594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM; 100 mg, q.d.)
Number of subjects: 39
Study 18307594 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN; 9 MU, t.i.w.)
Number of subjects: 39
Study 18307594 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon + Lamivudine combination (2 months of LAM followed by combination treatment)
Number of subjects: 39
Study 18307594 — intervention group
Group type: COMPARATOR
Intervention: Interferon monotherapy
Number of subjects: 39
Study 18307594 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 39
Study 16451437 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based caries preventive program including intensive oral hygiene instructions and supervised daily tooth brushing with fluoridated toothpaste.
Number of subjects: 856
Study 16451437 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only oral hygiene instructions sessions.
Number of subjects: 856
Study 12954659 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 2
Study 12954659 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in eugonadal men
Number of subjects: 2
Study 12954659 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 2
Study 12954659 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report diary assessment
Number of subjects: 2
Study 10615721 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐Structured Assessment for the Genetics of Alcoholism (SSAGA)
Number of subjects: 80
Study 10615721 — intervention group
Group type: COMPARATOR
Intervention: Schedule for Clinical Assessment in Neuropsychiatry (SCAN)
Number of subjects: 80
Study 8948943 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (455 patients)
Number of subjects: 455
Study 8948943 — intervention group
Group type: COMPARATOR
Intervention: Validation group (163 patients)
Number of subjects: 455
Study 8948943 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation for burn infection
Number of subjects: 455
Study 8948943 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified
Number of subjects: 455
Study 1757614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 224
Study 1757614 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 224
Study 6805647 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenergic-blocking agents (propranolol and phentolamine or propranolol alone) for three weeks
Number of subjects: 148
Study 6805647 — intervention group
Group type: COMPARATOR
Intervention: Long-acting propranolol
Number of subjects: 148
Study 30924762 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct EVT
Number of subjects: 200
Study 30924762 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy (EVT with IVT)
Number of subjects: 200
Study 28069629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube placement (with aspiration and lavage)
Number of subjects: 140
Study 28069629 — intervention group
Group type: COMPARATOR
Intervention: No NG placement (control)
Number of subjects: 140
Study 26180227 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical-model tailored, computer-assisted intervention, stage-matched manual, brief counseling, and 10-week post-hospitalization nicotine replacement
Number of subjects: 100
Study 26180227 — intervention group
Group type: COMPARATOR
Intervention: Usual care (on-unit nicotine replacement plus quit advice)
Number of subjects: 100
Study 24321149 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI)
Number of subjects: 36
Study 24321149 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade Roughness Breathiness Asthenia Strain (GRBAS) scale
Number of subjects: 36
Study 24321149 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS)
Number of subjects: 36
Study 21603988 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-in-water emulsion (WO1932)
Number of subjects: 66
Study 21603988 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 66
Study 20095333 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 1275
Study 20095333 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg/d
Number of subjects: 1275
Study 16464721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine gated single photon emission computed tomography perfusion imaging at years 1 and 3
Number of subjects: 0
Study 16464721 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy (specifics not provided)
Number of subjects: 0
Study 15561052 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial line leukocyte-depleting filter
Number of subjects: 110
Study 15561052 — intervention group
Group type: COMPARATOR
Intervention: Standard arterial line filter (Control)
Number of subjects: 110
Study 11940752 — intervention group
Group type: EXPERIMENTAL
Intervention: Colforsin daropate (0.75 microg x kg(‐1) x min(‐1) continuous infusion for 60 min)
Number of subjects: 36
Study 11940752 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (7.5 mL/hr continuous infusion)
Number of subjects: 36
Study 9806696 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral dextromethorphan
Number of subjects: 37
Study 9806696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8529331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (intravenous and oral)
Number of subjects: 10
Study 8529331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (oral)
Number of subjects: 10
Study 2131458 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable tablets containing pyridoxine and heat‐killed lactic bacteria
Number of subjects: 245
Study 2131458 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets with pyridoxine only
Number of subjects: 245
Study 662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-pressor test (direct stimulation)
Number of subjects: 0
Study 662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing a model exposed to the cold-pressor test (vicarious stimulation)
Number of subjects: 0
Study 662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing modeled verbal expressions of pain (vicarious stimulation)
Number of subjects: 0
Study 662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing the model express neither verbal expressions nor physical movements (minimal modeling condition)
Number of subjects: 0
Study 662568 — intervention group
Group type: COMPARATOR
Intervention: Direct stimulation vs. maximal modeling condition
Number of subjects: 0
Study 662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Two forms of modeling (observing and hearing pain expressions)
Number of subjects: 0
Study 662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stimulation and vicarious stimulation
Number of subjects: 0
Study 7115241 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic-feedback training (AFT) for highly susceptible subjects (Treatment Group I)
Number of subjects: 24
Study 7115241 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic-feedback training (AFT) for moderately susceptible subjects (Treatment Group II)
Number of subjects: 24
Study 7115241 — intervention group
Group type: COMPARATOR
Intervention: Control group (highly susceptible, Control Group III)
Number of subjects: 24
Study 7115241 — intervention group
Group type: COMPARATOR
Intervention: Control group (moderately susceptible, Control Group IV)
Number of subjects: 24
Study 31420787 — intervention group
Group type: EXPERIMENTAL
Intervention: PL‐ASA 325 mg
Number of subjects: 32
Study 31420787 — intervention group
Group type: EXPERIMENTAL
Intervention: PL‐ASA 650 mg
Number of subjects: 32
Study 31420787 — intervention group
Group type: COMPARATOR
Intervention: IR‐ASA 325 mg
Number of subjects: 32
Study 31420787 — intervention group
Group type: COMPARATOR
Intervention: IR‐ASA 650 mg
Number of subjects: 32
Study 31420787 — intervention group
Group type: EXPERIMENTAL
Intervention: PL‐ASA
Number of subjects: 32
Study 31420787 — intervention group
Group type: COMPARATOR
Intervention: IR‐ASA
Number of subjects: 32
Study 28696772 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation condition (simulators)
Number of subjects: 90
Study 28696772 — intervention group
Group type: COMPARATOR
Intervention: Control condition (controls)
Number of subjects: 90
Study 28696772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RT measures and immediate recognition (IR) subtest accuracy score
Number of subjects: 90
Study 25826678 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid administration (S-group)
Number of subjects: 60
Study 25826678 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fluid administration (R-group)
Number of subjects: 60
Study 24890250 — intervention group
Group type: EXPERIMENTAL
Intervention: Public involvement intervention
Number of subjects: 172
Study 24890250 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured preparation meeting and access to population-based data
Number of subjects: 172
Study 24890250 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group deliberations and wider public consultation
Number of subjects: 172
Study 24890250 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of key stakeholders in intervention design
Number of subjects: 172